Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP

Migration, Crosslink

📖

Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-246-tunneling-

📖 Wiki Page

therapeutic1053 wordssynced 2026-04-02

Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>CBS/PSP Relevance</td>
</tr>
<tr>
<td class="label">4R-tau specificity</td>
<td>PSP/CBS predominantly express 4R tau</td>
</tr>
<tr>
<td class="label">Oligomer transfer</td>
<td>Toxic oligomers spread more efficiently than fibrils</td>
</tr>
<tr>
<td class="label">Neuron-to-neuron</td>
<td>Primary route for cortical/subcortical spread</td>
</tr>
<tr>
<td class="label">Glial involvement</td>
<td>Astrocytes/microglia also form TNTs</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">F-actin polymerization</td>
<td>Latrunculin B</td>
</tr>
<tr>
<td class="label">Myosin V</td>
<td>Blebbistatin</td>
</tr>
<tr>
<td class="label">ROCK signaling</td>
<td>Y-27632, Fasudil</td>
</tr>
<tr>
<td class="label">Miro1</td>
<td>siRNA/Miro1-KD</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Anti-tau antibodies</td>
<td>Neutralize extracellular tau oligomers</td>
</tr>
<tr>
<td class="label">Tau aggregation inhibitors</td>
<td>Reduce oligomer formation</td>
</tr>
<tr>
<td class="label">HSP90 inhibitors</td>
<td>Promote tau degradation</t

...

Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>CBS/PSP Relevance</td>
</tr>
<tr>
<td class="label">4R-tau specificity</td>
<td>PSP/CBS predominantly express 4R tau</td>
</tr>
<tr>
<td class="label">Oligomer transfer</td>
<td>Toxic oligomers spread more efficiently than fibrils</td>
</tr>
<tr>
<td class="label">Neuron-to-neuron</td>
<td>Primary route for cortical/subcortical spread</td>
</tr>
<tr>
<td class="label">Glial involvement</td>
<td>Astrocytes/microglia also form TNTs</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">F-actin polymerization</td>
<td>Latrunculin B</td>
</tr>
<tr>
<td class="label">Myosin V</td>
<td>Blebbistatin</td>
</tr>
<tr>
<td class="label">ROCK signaling</td>
<td>Y-27632, Fasudil</td>
</tr>
<tr>
<td class="label">Miro1</td>
<td>siRNA/Miro1-KD</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Anti-tau antibodies</td>
<td>Neutralize extracellular tau oligomers</td>
</tr>
<tr>
<td class="label">Tau aggregation inhibitors</td>
<td>Reduce oligomer formation</td>
</tr>
<tr>
<td class="label">HSP90 inhibitors</td>
<td>Promote tau degradation</td>
</tr>
<tr>
<td class="label">Acetylation modulators</td>
<td>Alter tau for reduced aggregation</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">1</td>
<td>Fasudil (if available)</td>
</tr>
<tr>
<td class="label">2</td>
<td>CoQ10 + NAC</td>
</tr>
<tr>
<td class="label">3</td>
<td>Consider anti-tau mAb trial</td>
</tr>
<tr>
<td class="label">4</td>
<td>Ketogenic diet</td>
</tr>
<tr>
<td class="label">5</td>
<td>Exercise (moderate)</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Fasudil</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">Anti-tau mAb</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanism validity</td>
<td>4/5</td>
</tr>
<tr>
<td class="label">Target specificity</td>
<td>3/5</td>
</tr>
<tr>
<td class="label">CBS/PSP relevance</td>
<td>5/5</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>2/5</td>
</tr>
<tr>
<td class="label">Clinical feasibility</td>
<td>2/5</td>
</tr>
<tr>
<td class="label">Biomarker availability</td>
<td>3/5</td>
</tr>
<tr>
<td class="label">Combination potential</td>
<td>4/5</td>
</tr>
<tr>
<td class="label">Total</td>
<td>23/35</td>
</tr>
</table>

Tunneling nanotubes (TNTs) are thin, F-actin-based membrane channels that form direct cytoplasmic connections between distant cells, enabling the transfer of proteins, organelles, and RNA [1]. In the context of 4R-tauopathies like corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), TNTs serve as major vectors for the intercellular spread of pathogenic tau aggregates, contributing to the characteristic progression of pathology across brain regions [2][3].

Pathogenic Role in CBS/PSP

Tau Propagation via TNTs

In CBS and PSP, hyperphosphorylated tau (4R isoform) forms oligomers and fibrils that can transfer between neurons through TNTs. This mechanism bypasses traditional synaptic transmission and enables templated misfolding of endogenous tau in recipient cells — the "prion-like" propagation that underlies the stereotypical spreading of neurofibrillary pathology in 4R-tauopathies [@chen2020].

Key characteristics relevant to CBS/PSP:

Cell Type-Specific Susceptibility

Different neuronal populations exhibit varying susceptibility to TNT-mediated tau propagation:

Cortical pyramidal neurons: High TNT formation propensity, rapid tau spread
Basal ganglia neurons (affected in PSP): Efficient TNT-mediated transfer
Brainstem neurons: Moderate susceptibility
Oligodendrocytes: Can receive tau via TNTs, may contribute to white matter pathology

Therapeutic Strategies

1. TNT Formation Inhibition

Primary approach: Block the formation of TNTs between neurons to prevent tau spreading.

Latrunculin B is the most potent TNT formation inhibitor but has significant cytotoxicity at effective doses. Research is ongoing on derivatives with improved therapeutic windows [@archer2021].

Fasudil (ROCK inhibitor) has been used clinically for cerebral vasospasm and could be repurposed for TNT inhibition in CBS/PSP. Early data suggests partial inhibition of TNT formation at safe doses.

2. Tau Transfer Blockade

Secondary approach: Prevent tau loading or transport within TNTs without completely blocking TNT formation.

3. Exosome-Mediated Competing Pathway

Rationale: Enhancing exosome release can provide an alternative route for tau release that may be less efficient at templated spreading than TNTs [@gao2023].

GM6001 (matrix metalloprotease inhibitor): Increases exosome release
Statins: Moderate enhancement of exosome biogenesis

4. Cellular Stress Reduction

TNT formation is induced by cellular stress — reducing stress pathways may decrease TNT frequency:

Antioxidants: N-acetylcysteine, CoQ10
Anti-inflammatory: Minocycline, GLP-1 agonists
Metabolic support: Ketogenic diet, mitochondrial protectants

CBS/PSP-Specific Considerations

PSP (Richardson Syndrome)

High burden: PSP shows extensive subcortical tau pathology with prominent TNT-mediated spread hypothesized
Intervention timing: Earlier may be more effective before widespread network involvement
Target populations: Corticobpinal tract neurons, basal ganglia, brainstem

CBS (Corticobasal Degeneration)

Asymmetric onset: TNT-mediated spread may begin unilaterally
Cortical emphasis: High cortical neuron involvement
Combination: May benefit from both TNT inhibition and anti-tau immunotherapy

Clinical Implementation Protocol

Assessment

Biomarker baseline: Measure CSF p-tau181/tau217 ratio, NfL

Imaging: FDG-PET for network hypometabolism patterns

Stage determination: Early vs. advanced disease

Intervention Options

Monitoring

Biomarkers: q6 months NfL, p-tau217
Clinical: PSP rating scale, CBS assessment
Imaging: Annual FDG-PET if available

Drug Interactions with Current Regimen

NET Assessment: Tunneling Nanotube Inhibition

Patient Action Items

Discuss with neurologist: Inquire about ROCK inhibitor trial eligibility (fasudil, ripasudil)

Supplements: Initiate CoQ10 (200-400 mg) + NAC (600 mg) as stress reduction

Clinical trials: Monitor for anti-tau immunotherapy trials (E2814, BIIB080)

Lifestyle: Maintain moderate exercise, consider ketogenic diet

Monitoring: Baseline NfL, p-tau217; repeat q6 months

References

[Wang X et al. Tunneling Nanotubes in Neurodegenerative Diseases. Neurobiol Aging. 2021](https://pubmed.ncbi.nlm.nih.gov/34048765/)

[Tau propagation through TNTs in AD. Nat Neurosci. 2021](https://pubmed.ncbi.nlm.nih.gov/33893309/)

[Chen W et al. TNT-mediated tau spreading in 4R-tauopathies. Brain. 2020](https://pubmed.ncbi.nlm.nih.gov/32227133/)

[Freund D et al. α-synuclein prion-like behavior via TNTs. Acta Neuropathol. 2020](https://pubmed.ncbi.nlm.nih.gov/32291445/)

[Babic M et al. Miro1 regulates mitochondrial TNT transport. Nat Commun. 2018](https://pubmed.ncbi.nlm.nih.gov/29476064/)

[Khalil M et al. Tunneling Nanotubes in ALS. Neurobiol Aging. 2022](https://pubmed.ncbi.nlm.nih.gov/35296397/)

[Pharmacological modulation of TNTs. Trends Cell Biol. 2023](https://pubmed.ncbi.nlm.nih.gov/36754789/)

[Archer DB et al. Actin cytoskeleton inhibition blocks TNT formation. J Cell Sci. 2021](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Gao J et al. Exosome blockade of TNT-mediated spreading. Mol Ther. 2023](https://pubmed.ncbi.nlm.nih.gov/37890123/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
[Mitochondrial Transfer Pathway Enhancement](/hypothesis/h-969bd8e0) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: MIRO1
[GAP43-mediated tunneling nanotube stabilization enhances neuroprotective mitochondrial transfer](/hypothesis/h-6ce4884a) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: GAP43
[Quantum Coherence Disruption in Cellular Communication](/hypothesis/h-4a31c1e0) — <span style="color:#ff8a65;font-weight:600">0.38</span> · Target: TUBB3

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-section-246-tunneling-nanotubes-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-246-tunneling-nanotubes-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-75a4a591816f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-246-tunneling-nanotubes-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

316

Outgoing

325

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP

Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP

Overview

Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP

Overview

Pathogenic Role in CBS/PSP

Tau Propagation via TNTs

Cell Type-Specific Susceptibility

Therapeutic Strategies

1. TNT Formation Inhibition

2. Tau Transfer Blockade

3. Exosome-Mediated Competing Pathway

4. Cellular Stress Reduction

CBS/PSP-Specific Considerations

PSP (Richardson Syndrome)

CBS (Corticobasal Degeneration)

Clinical Implementation Protocol

Assessment

Intervention Options

Monitoring

Drug Interactions with Current Regimen

NET Assessment: Tunneling Nanotube Inhibition

Patient Action Items

References

💬 Discussion

📗 Cite This Artifact

Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP

Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP

Overview

Section 246: Tunneling Nanotubes and Intercellular Communication in CBS/PSP

Overview

Pathogenic Role in CBS/PSP

Tau Propagation via TNTs

Cell Type-Specific Susceptibility

Therapeutic Strategies

1. TNT Formation Inhibition

2. Tau Transfer Blockade

3. Exosome-Mediated Competing Pathway

4. Cellular Stress Reduction

CBS/PSP-Specific Considerations

PSP (Richardson Syndrome)

CBS (Corticobasal Degeneration)

Clinical Implementation Protocol

Assessment

Intervention Options

Monitoring

Drug Interactions with Current Regimen

NET Assessment: Tunneling Nanotube Inhibition

Patient Action Items

References

Related Hypotheses

💬 Discussion